Status:
COMPLETED
Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim
Lead Sponsor:
GlaxoSmithKline
Conditions:
Immune Thrombocytopenic Purpura
Eligibility:
All Genders
18+ years
Brief Summary
Chronic immune thrombocytopenic purpura (ITP) is characterized by low platelet counts and the risk of severe bleeding complications. The two recently introduced TPO-RA drugs, namely, eltrombopag and r...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Adults 18 years and older diagnosed with chronic ITP
- Switched to eltrombopag or romiplostim a minimum of 4 weeks prior to index date
- Received corticosteroids, rituximab, or one TPO-receptor agonist as prior primary therapy before switching to eltrombopag or romiplostim
- Medical history must be available from chronic ITP diagnosis through to most recent office visit
- Patients who complete the self-administered questionnaire were the same patients whose medical charts were reviewed
- Exclusion criteria
- Age less than 18 years old
Exclusion
Key Trial Info
Start Date :
November 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
280 Patients enrolled
Trial Details
Trial ID
NCT01439321
Start Date
November 1 2010
End Date
June 1 2011
Last Update
June 25 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.